方舟生物医药

ABIO NASDAQ
6.92
-0.28
-3.89%
盘后: 6.92 0 0.00% 16:00 07/18 EDT
开盘
7.15
昨收
7.20
最高
7.27
最低
6.87
成交量
1.78万
成交均量(3M)
80.27万
52周最高
23.04
52周最低
4.725
换手率
1.20%
市值
1,007.24万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供方舟生物医药 ABIO股票价格,方舟生物医药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
展开 >

最近浏览

名称
价格
涨跌幅